madman
Super Moderator
* This narrative review integrates randomized and real‑world evidence on TRT‑associated AF, AKI, and PE, translates these signals into practical guidance for patient selection and safety monitoring, and outlines key methodological and mechanistic priorities for future research. In contemporary practice, the objective is precision: select the right patient, aim for stable exposure, and follow a protocolized safety plan.
ABSTRACT
Testosterone replacement therapy (TRT) is an effective treatment for male hypogonadism of defined etiology, but its safety profile continues to prompt clinical and regulatory scrutiny. Beyond major adverse cardiovascular events (MACE), attention has shifted toward clinically important non‑MACE outcomes, notably atrial fibrillation (AF), acute kidney injury (AKI), and venous thromboembolism, including pulmonary embolism (PE). The landmark TRAVERSE randomized safety trial in men with hypogonadism and established or high cardiovascular risk demonstrated non‑inferiority of TRT vs. placebo for MACE, but reported higher event rates of AF, AKI, and PE in the testosterone group. Observational datasets suggest a possible early venous thromboembolism risk window after TRT initiation (often within the first 3–6 months), although estimates vary and residual confounding remains a major limitation. In February 2025, the US Food and Drug Administration updated testosterone product labeling: the boxed warning for major cardiovascular events was removed, while a class‑wide warning regarding blood pressure increases was added based on ambulatory blood pressure monitoring data. This narrative review integrates randomized and real‑world evidence on TRT‑associated AF, AKI, and PE, translates these signals into practical guidance for patient selection and safety monitoring, and outlines key methodological and mechanistic priorities for future research. In contemporary practice, the objective is precision: select the right patient, aim for stable exposure, and follow a protocolized safety plan.
CONCLUSIONS
In appropriately selected men with confirmed hypogonadism, TRT administered with guideline‑concordant titration and monitoring has not been shown to increase the risk of MACE, a conclusion strongly supported by large, randomized safety data (including the TRAVERSE) and reflected in recent regulatory updates. Nonetheless, “MACE neutrality” should not be conflated with comprehensive safety neutrality across all clinically meaningful outcomes.
Across TRAVERSE and several real‑world datasets, non‑MACE signals (AF, AKI, and PE) have emerged with sufficient consistency, timing (often early after initiation), and biological plausibility to warrant practical risk‑mitigation in routine care. While causality for these less frequent endpoints cannot be considered definitive, waiting for perfect certainty risks missing preventable harm in vulnerable phenotypes.
The clinical endpoint is therefore precision rather than prohibition: treat the right patient, with the right formulation and dose, and with a structured safety plan. Phenotype-guided selection (Table 2), preference for more stable exposure where feasible, and structured monitoring with clear action thresholds (Table 1) represent a pragmatic risk-mitigation approach that is clinically reasonable today but is not yet validated as an evidence-based standard for reducing arrhythmic, thromboembolic, or renal events. In our view, this approach is sufficiently grounded to inform current practice in appropriately selected patients, while remaining provisional until prospective studies clarify absolute risk, causal mechanisms, and the effectiveness of phenotype-guided monitoring strategies.
In short, testosterone therapy is neither inherently safe nor inherently dangerous; its net safety depends on a correct indication, an exposure profile that matches patient risk, and continuous, pre‑specified monitoring.
ABSTRACT
Testosterone replacement therapy (TRT) is an effective treatment for male hypogonadism of defined etiology, but its safety profile continues to prompt clinical and regulatory scrutiny. Beyond major adverse cardiovascular events (MACE), attention has shifted toward clinically important non‑MACE outcomes, notably atrial fibrillation (AF), acute kidney injury (AKI), and venous thromboembolism, including pulmonary embolism (PE). The landmark TRAVERSE randomized safety trial in men with hypogonadism and established or high cardiovascular risk demonstrated non‑inferiority of TRT vs. placebo for MACE, but reported higher event rates of AF, AKI, and PE in the testosterone group. Observational datasets suggest a possible early venous thromboembolism risk window after TRT initiation (often within the first 3–6 months), although estimates vary and residual confounding remains a major limitation. In February 2025, the US Food and Drug Administration updated testosterone product labeling: the boxed warning for major cardiovascular events was removed, while a class‑wide warning regarding blood pressure increases was added based on ambulatory blood pressure monitoring data. This narrative review integrates randomized and real‑world evidence on TRT‑associated AF, AKI, and PE, translates these signals into practical guidance for patient selection and safety monitoring, and outlines key methodological and mechanistic priorities for future research. In contemporary practice, the objective is precision: select the right patient, aim for stable exposure, and follow a protocolized safety plan.
CONCLUSIONS
In appropriately selected men with confirmed hypogonadism, TRT administered with guideline‑concordant titration and monitoring has not been shown to increase the risk of MACE, a conclusion strongly supported by large, randomized safety data (including the TRAVERSE) and reflected in recent regulatory updates. Nonetheless, “MACE neutrality” should not be conflated with comprehensive safety neutrality across all clinically meaningful outcomes.
Across TRAVERSE and several real‑world datasets, non‑MACE signals (AF, AKI, and PE) have emerged with sufficient consistency, timing (often early after initiation), and biological plausibility to warrant practical risk‑mitigation in routine care. While causality for these less frequent endpoints cannot be considered definitive, waiting for perfect certainty risks missing preventable harm in vulnerable phenotypes.
The clinical endpoint is therefore precision rather than prohibition: treat the right patient, with the right formulation and dose, and with a structured safety plan. Phenotype-guided selection (Table 2), preference for more stable exposure where feasible, and structured monitoring with clear action thresholds (Table 1) represent a pragmatic risk-mitigation approach that is clinically reasonable today but is not yet validated as an evidence-based standard for reducing arrhythmic, thromboembolic, or renal events. In our view, this approach is sufficiently grounded to inform current practice in appropriately selected patients, while remaining provisional until prospective studies clarify absolute risk, causal mechanisms, and the effectiveness of phenotype-guided monitoring strategies.
In short, testosterone therapy is neither inherently safe nor inherently dangerous; its net safety depends on a correct indication, an exposure profile that matches patient risk, and continuous, pre‑specified monitoring.
